WIRE — Novo sostiene que las campañas publicitarias de Lilly se basan en comparaciones desactualizadas sobre pérdida de peso, utilizando dosis inferiores de su propio medicamento contra la obesidad, Wegovy.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.